Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pozen has received a total of $20 million in milestone payments from GlaxoSmithKline for the FDA approval of, and Glaxo's intent to commercialize, Treximet for the acute treatment of migraine in adults.
Subscribe to our email newsletter
Treximet is said to be the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, and an anti-inflammatory pain reliever in a single tablet. Treximet contains 85mg sumatriptan, formulated with RT Technology, and 500mg naproxen sodium.
John Plachetka, chairman, president and CEO of Pozen, said: “We are extremely pleased that the FDA has approved Treximet and are very excited that GSK has already begun the process to commercialize the drug with expected availability in pharmacies by mid-May of 2008.”